NASDAQ:AURA Aura Biosciences - AURA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $9.28 +0.40 (+4.50%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.89▼$9.4050-Day Range$8.88▼$12.1152-Week Range$8.63▼$24.83Volume126,085 shsAverage Volume178,807 shsMarket Capitalization$350.78 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Aura Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside169.4% Upside$25.00 Price TargetShort InterestBearish4.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$3,960 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.17) to ($2.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.62 out of 5 starsMedical Sector821st out of 996 stocksBiological Products, Except Diagnostic Industry140th out of 165 stocks 3.5 Analyst's Opinion Consensus RatingAura Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.00, Aura Biosciences has a forecasted upside of 169.4% from its current price of $9.28.Amount of Analyst CoverageAura Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.83% of the float of Aura Biosciences has been sold short.Short Interest Ratio / Days to CoverAura Biosciences has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Aura Biosciences has recently increased by 30.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAura Biosciences does not currently pay a dividend.Dividend GrowthAura Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AURA. Previous Next 0.6 News and Social Media Coverage News SentimentAura Biosciences has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aura Biosciences this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Aura Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aura Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,960.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Aura Biosciences is held by insiders.Percentage Held by Institutions55.63% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aura Biosciences are expected to decrease in the coming year, from ($2.17) to ($2.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aura Biosciences is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aura Biosciences is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAura Biosciences has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aura Biosciences (NASDAQ:AURA) StockAura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.Read More Receive AURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AURA Stock News HeadlinesMarch 20, 2023 | benzinga.comAura Biosciences Stock (NASDAQ:AURA), DividendsMarch 20, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Top Glove Bhd (TPGVF), Aura Biosciences Inc (AURA)April 2, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.March 15, 2023 | finance.yahoo.comAura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational HighlightsMarch 14, 2023 | marketwatch.comCoating Buffer Market Size, Share & Trends Analysis Report By Product, By Application, By Region, And Segment Forecasts, 2023 - 2030February 24, 2023 | finance.yahoo.comAura Biosciences Releases Data Presentation Of Eye Cancer CandidateFebruary 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Aura Biosciences Inc (AURA) and Amedisys (AMED)February 16, 2023 | markets.businessinsider.comJMP Securities Reaffirms Their Buy Rating on Aura Biosciences Inc (AURA)April 2, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.February 16, 2023 | msn.comAura rises after updating Phase 2 data for eye cancer therapyFebruary 16, 2023 | finance.yahoo.comAura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal AdministrationFebruary 10, 2023 | finance.yahoo.comWhy Shares of Aura Biosciences Jumped This WeekJanuary 21, 2023 | nasdaq.comChiesi Ventures, Inc. Cuts Stake in Aura Biosciences Inc (AURA)December 24, 2022 | finance.yahoo.comInstitutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 11% drop adds to a year lossesDecember 1, 2022 | marketwatch.comAura Biosciences Shares Drop 19% After Public Offering PricesDecember 1, 2022 | finance.yahoo.comAura Biosciences Announces Pricing of Public Offering of Common StockNovember 30, 2022 | seekingalpha.comAura Biosciences announces stock offering, size not disclosedNovember 24, 2022 | finance.yahoo.comAura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this yearNovember 11, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Paragon 28 (FNA) and Aura Biosciences Inc (AURA)November 10, 2022 | finance.yahoo.comAura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal MelanomaNovember 10, 2022 | finance.yahoo.comAura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational HighlightsOctober 6, 2022 | finance.yahoo.comHere's Why We're Not Too Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn SituationOctober 4, 2022 | finance.yahoo.comPositive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space PlatformOctober 3, 2022 | seekingalpha.comAura sheds 16% after Phase 2 data for eye cancer therapyOctober 3, 2022 | finance.yahoo.comAura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology DrugOctober 3, 2022 | finance.yahoo.comAura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022October 3, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Aura Biosciences Inc (AURA)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AURA Company Calendar Last Earnings3/15/2023Today4/01/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AURA CUSIPN/A CIK1501796 Webwww.aurabiosciences.com Phone617-500-8864FaxN/AEmployees52Year FoundedN/APrice Target and Rating Average Stock Price Forecast$25.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+169.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-40.25% Return on Assets-36.04% Debt Debt-to-Equity RatioN/A Current Ratio18.81 Quick Ratio18.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.67 per share Price / Book1.39Miscellaneous Outstanding Shares37,800,000Free Float35,910,000Market Cap$350.78 million OptionableNot Optionable Beta0.12 Key ExecutivesDr. Elisabet de los Pinos Ph.D. (Age 49)Founder, CEO, Pres & Director Comp: $676.62kMs. Julie B. Feder (Age 53)CFO, Sec. & Treasurer Comp: $505.45kDr. Cadmus Collins Rich CPE (Age 58)M.B.A., M.D., MBA, Chief Medical Officer and Head of R&D Comp: $564.22kDr. Mark A. De Rosch Ph.D. (Age 59)Chief Operating Officer Mr. Paulo CarvalhoVP of Technical OperationsMr. Joseph LyonsVP of HRMs. Michele Keough M.B.A.Sr. VP of Project Management and Device Supply ChainMore ExecutivesKey CompetitorsTarsus PharmaceuticalsNASDAQ:TARSVigil NeuroscienceNASDAQ:VIGLMonte Rosa TherapeuticsNASDAQ:GLUEAlloVirNASDAQ:ALVRVoyager TherapeuticsNASDAQ:VYGRView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCBought 414,987 shares on 2/15/2023Ownership: 2.723%Morgan StanleyBought 9,451 shares on 2/15/2023Ownership: 0.220%Alps Advisors Inc.Bought 24,432 shares on 2/15/2023Ownership: 0.083%Water Island Capital LLCBought 12,800 shares on 2/14/2023Ownership: 0.080%Alyeska Investment Group L.P.Bought 21,456 shares on 2/14/2023Ownership: 0.073%View All Insider TransactionsView All Institutional Transactions AURA Stock - Frequently Asked Questions Should I buy or sell Aura Biosciences stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AURA shares. View AURA analyst ratings or view top-rated stocks. What is Aura Biosciences' stock price forecast for 2023? 1 brokerages have issued 12-month price objectives for Aura Biosciences' shares. Their AURA share price forecasts range from $25.00 to $25.00. On average, they expect the company's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 169.4% from the stock's current price. View analysts price targets for AURA or view top-rated stocks among Wall Street analysts. How have AURA shares performed in 2023? Aura Biosciences' stock was trading at $10.50 at the beginning of 2023. Since then, AURA shares have decreased by 11.6% and is now trading at $9.28. View the best growth stocks for 2023 here. Are investors shorting Aura Biosciences? Aura Biosciences saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,250,000 shares, an increase of 30.2% from the February 28th total of 960,000 shares. Based on an average daily trading volume, of 115,300 shares, the days-to-cover ratio is currently 10.8 days. Approximately 4.8% of the shares of the company are short sold. View Aura Biosciences' Short Interest. When is Aura Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our AURA earnings forecast. How were Aura Biosciences' earnings last quarter? Aura Biosciences, Inc. (NASDAQ:AURA) announced its earnings results on Wednesday, March, 15th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.06. What ETFs hold Aura Biosciences' stock? ETFs with the largest weight of Aura Biosciences (NASDAQ:AURA) stock in their portfolio include AltShares Event-Driven ET (EVNT).ALPS Medical Breakthroughs ETF (SBIO). When did Aura Biosciences IPO? (AURA) raised $81 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 5,400,000 shares at a price of $14.00-$16.00 per share. What is Aura Biosciences' stock symbol? Aura Biosciences trades on the NASDAQ under the ticker symbol "AURA." How do I buy shares of Aura Biosciences? Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aura Biosciences' stock price today? One share of AURA stock can currently be purchased for approximately $9.28. How much money does Aura Biosciences make? Aura Biosciences (NASDAQ:AURA) has a market capitalization of $350.78 million. The company earns $-58,760,000.00 in net income (profit) each year or ($1.96) on an earnings per share basis. How can I contact Aura Biosciences? The official website for the company is www.aurabiosciences.com. The company can be reached via phone at 617-500-8864 or via email at aura@argotpartners.com. This page (NASDAQ:AURA) was last updated on 4/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.